| Literature DB >> 30960498 |
Ana Rey-Rico1, Magali Cucchiarini2.
Abstract
Controlled delivery of gene transfer vectors is a powerful strategy to enhance the temporal and spatial presentation of therapeutic agents in a defined target. Hydrogels are adapted biomaterials for gene delivery capable of acting as a localized depot of genes while maintaining the long term local availability of DNA vectors at a specific location. Supramolecular hydrogels based on cyclodextrins (CDs) have attracted considerable attention as potential biomaterials in a broad range of drug delivery applications. Their unique characteristics of thixotropicity and low cytotoxicity due to their production under mild conditions make them potential candidates to form injectable delivery systems. This work aims to provide an overview of the use of CD-based polypseudorotaxane hydrogels as controlled gene delivery systems for different applications in regenerative medicine.Entities:
Keywords: controlled gene delivery; cyclodextrin-based polypseudorotaxane hydrogels; gene transfer; nonviral vectors; supramolecular hydrogels; viral vectors
Year: 2019 PMID: 30960498 PMCID: PMC6473339 DOI: 10.3390/polym11030514
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1Structure of cyclodextrins. Two-dimensional sequences of α-CDs (CID: 444913) (A), β-CDs (CID: 444041) (B), and γ-CDs (CID: 5287407) (C) were obtained from PubChem Compound. Three-dimensional (3D) structures of the different compounds were drawn with ChemBioOffice 2012 (Chem3D Pro 13; PerkinElmer Informatics).
Controlled delivery of nonviral vectors via supramolecular-based CD hydrogels.
| Polymers/CDs | Vectors | Outcomes | Approaches | Targets | References |
|---|---|---|---|---|---|
| PF68-PLL/α-CD | pDNA-GFP | Sustained pDNA delivery for 80 h; transfection efficiency ~14% | mouse fibroblast cells 3T3 | n.s. | [ |
| MPEG-PCL-PDMAEMA/α-CD | pDNA- | Sustained release of pDNA up to 6 days; transfection efficiency comparable to freshly prepared PEI polyplexes | COS-7 cells | n.s. | [ |
| PEG-α-CD-cross-linked PVDT | pDNA- | Efficient reverse gene transfection of cells cultured on the gel surface | COS-7 cells | n.s. | [ |
| MPEG-PCL-PEI/α-CD MPEG-PCL-PEIFA/α-CD | pDNA-GFP | Sustained release of pDNA for 7 days; transfection efficiency of 63% at optimal weight ratio of 1.5; significant inhibition of therapeutic resistant tumor growth with high expression of Bcl-2 proteins | HEK293 cells, tumor model (BALB/c nude mice) | tumor | [ |
| MPEG-PLLD-Arg/α-CD | pMMP-9 | Controlled release for 6 days; transfection efficiency up to 72%; sustained tumor growth inhibition after 21 days with good biocompatibility | HNE-1 cells, nude mice bearing HNE-1 tumors | tumor | [ |
Abbreviations: CD: cyclodextrin; Pluronic® F68; PLL: poly(l-lysine); α-CD: alpha-CD; MPEG-PCL-PDMAEM:. methoxy-poly(ethylene glycol)-b-poly(ε-caprolactone)-b-poly[2-(dimethylamino)ethyl methacrylate]; PEG: poly-ethylene glycol; β-CD: beta-CD; PVDT: poly-2-vinyl-4,6-diamino-1,3,5-triazine; PEI: poly(ethylene imine); PLLD-Arginine-functionalized PLL dendron; pDNA: plasmid DNA; GFP: green fluorescent protein; luc: luciferase; Nur 77: Bcl-2 (B-cell lymphoma 2) conversion Nur77 gene; FA: folic acid; MMP-9: matrix metalloproteinase 9; HNE-1: human nasopharyngeal carcinoma HNE-1 cells; n.s.: not specified.
Controlled delivery of viral vectors via supramolecular-based cyclodextrins (CD) hydrogels.
| Polymers/CDs | Vectors | Outcomes | Approaches | Targets | References |
|---|---|---|---|---|---|
| CS (or HA)/PF68/α-CD | rAAV- | Sustained release for 21 days; CS (or HA)/PF68/α-CD gels resulted in the highest rAAV concentrations and sustained levels of transgene expression over time | hMSCs | cartilage repair | [ |
Abbreviations: CD: cyclodextrin; CS: chondroitin sulfate; HA: hyaluronic acid; PF68: Pluronic® F68; T908: Tetronic® 908; α-CD: alpha-CD; hMSCs: human bone marrow-derived mesenchymal stem cells.
Figure 2Controlled delivery of rAAV-lacZ (A) or rAAV-FLAG-hsox9 (B) via polypseudorataxane hydrogels. Pellets were cultured in the absence (positive control; free rAAV form) or presence of rAAV-loaded hydrogels systems (Pluronic® F68 (PF68)/ chondroitin sulfate (CS)/alpha-cyclodextrins (α-CD) or PF68/ hyaluronic acid (HA)/α-CD) for 21 days and monitored for chondrogenic differentiation (A,B: Toluidine blue staining: magnification ×4, all representative data) and β-galactosidase activity (A: β-gal immunounoreactivity: magnification ×20, all representative data).